MS-Perspektive - The Multiple Sclerosis Podcast25 Sep 2025

#133: ECTRIMS 2025 MS Highlights: First Insights for Patients

Read the full blog article here: ms-perspektive.com – ECTRIMS 2025 MS Highlights

ECTRIMS 2025 MS Highlights: First Insights for Patients

ECTRIMS is the world's largest MS conference, and in 2025 it takes place in Barcelona. Thousands of researchers and clinicians share the newest findings on multiple sclerosis. In this episode, we look at the first highlights from the press releases:

Early biomarkers for silent progression (PIRA)
How menopause may influence MS and comorbidities
The role of ultra-processed foods in relapses and MRI lesions
Environmental risk: pediatric ozone exposure
Ocrelizumab's strong relapse control—and its limits against progression

Learn what this research could mean for you, why statistical significance isn't always clinical significance, and why these insights matter for the future of MS care.

More iformation on: ectrims.eu/ectrims2025/

See you soon and try to make the best out of your life,
Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.

🔗 References

For those who would like to dive deeper, here are the scientific abstracts presented at ECTRIMS 2025:

PIRA biomarkers – Landwehr A., et al. Proteomic Signatures of PIRA: Distinct proteins in cerebrospinal fluid are associated with progression independent of relapse activity in multiple sclerosis. ECTRIMS 2025, Barcelona.
Menopause and MS – Şimşek SY. Impact of Menopause on Initial Clinical Presentation and Comorbidities in Women with Multiple Sclerosis: A Comparative Study with Age-Matched Men. ECTRIMS 2025, Barcelona.
Ultra-processed foods – Dalla Costa G. Association of Ultra-Processed Food Intake with Increased MS Disease Activity: Findings from the BENEFIT Trial. ECTRIMS 2025, Barcelona.
Pediatric ozone exposure – Pugliatti M., Bergamaschi R., Pilotto A., Ghezzi A., et al. Exposure to ozone is associated with an increased risk of pediatric multiple sclerosis (pedMS): the PEDIGREE study. Abstract IMS25-LBA-176. ECTRIMS 2025, Barcelona.
Ocrelizumab – Roos I. Real-world effectiveness of ocrelizumab in multiple sclerosis: a multi-registry observational cohort study. ECTRIMS 2025, Barcelona.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(192)

#190: Living with multiple sclerosis. Gabriela's story and the "(un)seen faces of MS" Art Project

https://ms-perspektive.de/en/190-unseen-faces-of-ms/Living with multiple sclerosis often means experiencing symptoms that others cannot see. Austrian artist Gabriela Romagna shares her journey to an M...

4 Nov 32min

#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026

How could new imaging in MS help us understand progression and develop better treatments? In this episode, I explore key insights from Daniel Reich's MSToronto2026 lecture and related research. Learn ...

28 Okt 15min

#188: Jan Van Amstel on EMSP's Four-Year Presidency and the Future of MS Advocacy in Europe

"Get rid of MS as soon as possible and make ourselves superfluous." — Jan van Amstel What can a stronger European voice achieve for people living with MS? In episode #188, EMSP President Jan van Amste...

21 Okt 31min

#187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

Aging in multiple sclerosis brings new questions about relapses, gradual progression and treatment choices. In episode 187, Dr. Yi Chao Foong, an MS neurologist and researcher in Tasmania, explains wh...

14 Okt 29min

#186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

Why can multiple sclerosis progress even when relapses are well controlled? In episode 186, I speak with Prof. Manuel Friese about the next challenge in MS research: protecting nerve cells from damage...

7 Okt 43min

#185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

An MS diagnosis can depend on where you live, whether you can reach a neurologist and how quickly you can get an MRI. In this episode, Nele speaks with neurologist and neuroimmunologist Dr. Enrique Go...

30 Sep 36min

#184: MS treatment across the disease course – treat early, think long-term, don't give up too soon with Prof. Klaus Schmierer

Read the full blog post and interview here: https://ms-perspektive.de/en/184-klaus-schmierer/ How early should MS treatment start, how strongly should we treat, and is there ever a point when it becom...

23 Sep 41min

#183: Silent progression in MS. Can we really detect it early?

Can we detect gradual MS progression before it becomes obvious? In this episode, I look at what current research can — and cannot — tell us about subtle worsening without an obvious relapse. The key d...

16 Sep 34min